Gushengtang Holdings Limited
3.08
EUR
+0.02
(+0.65%)
ISIN
KYG4212K1040
CUSIP
G4212K104
Return %
Stock
S&P 500
1Y
-4.94
14.20
3Y
-41.89
81.12
5Y
-70.04
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Semi-annual Revenue
CNY
•
in mil. unless spec.Semi-annual Earnings Per Share
CNY
•
in mil. unless spec.Semi-annual Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Zhi Liang Tu
- Full Time Employees
- 3,551
- Sector
- Technology services
- Industry
- Internet software/Services
- Address
- No. 419 Qingsha Road Guangzhou GD China 50470
- IPO Date
- Dec 10, 2021
- Website
- gstzy.cn
- Similar Companies
- Business
- Gushengtang Holdings Limited, founded in 2010 and headquartered in Guangzhou, China, is an investment holding company primarily engaged in the provision of traditional Chinese medicine (TCM) medical and health services in the People's Republic of China. The company operates through two main segments: provision of healthcare services and sales of healthcare products. Its core products include ejiao, cordyceps, cubilose, dendrobium, American ginseng, and other medicinal materials, supplemented by a variety of herbal medicines, dietary supplements, and health-related products. Gushengtang provides a comprehensive range of healthcare services, including traditional Chinese medicine consultation, treatment services such as acupuncture, moxibustion, traditional massage, and operates multiple TCM clinics and offline medical institutions alongside online healthcare platforms. Recent major company developments include a strategic emphasis on integrating AI technology with traditional Chinese medicine, aimed at enhancing their medical and commercial applications, particularly the AI Traditional Chinese Medicine Avatar product, which is being introduced to young doctors. The company has also actively engaged in an extensive share repurchase program during 2025, reflecting its financial confidence and commitment to shareholder value. Additionally, Gushengtang changed its corporate name from Gushengtang (Cayman) Ltd. to Gushengtang Holdings Limited in September 2021, indicating a significant organizational restructuring. The company continues to expand its operational scale with a reported revenue growth from approximately RMB 1.37 billion in 2021 to over RMB 3.02 billion by the end of 2024, supported by a strong supply chain and investment management services related to its healthcare business. Gushengtang targets a broad customer base within China, from individual consumers seeking traditional herbal remedies to patients requiring TCM-based healthcare services delivered through both physical clinics and e-commerce platforms. The company's business strategy includes wholesale and retail pharmaceutical product sales and investment in supply chain management to optimize the procurement and distribution of TCM products. Its diversified service and product offerings position Gushengtang as a leading player in the traditional Chinese medicine industry in China, combining traditional expertise with modern technological advancements to strengthen its market presence and service delivery.